- [0032] In some embodiments the antigen-binding molecule comprises:
 - [0033] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0034] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0035] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
 - [0036] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
 - [0037] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0038] LC-CDR1 having the amino acid sequence of SEQ ID NO:89
 - [0039] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
 - [0040] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0041] In some embodiments the antigen-binding molecule comprises:
 - [0042] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0043] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0044] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
 - [0045] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
 - [0046] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0047] LC-CDR1 having the amino acid sequence of SEQ ID NO:90
 - [0048] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
 - [0049] LC-CDR3 having the amino acid sequence of SEQ ID NO:96.
- [0050] In some embodiments the antigen-binding molecule comprises:
 - [0051] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0052] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0053] HC-CDR2 having the amino acid sequence of SEQ ID NO:44
 - [0054] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and
 - [0055] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0056] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - [0057] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
 - [0058] LC-CDR3 having the amino acid sequence of SEQ ID NO:98.
- [0059] In some embodiments the antigen-binding molecule comprises:
 - [0060] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0061] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0062] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
 - [0063] HC-CDR3 having the amino acid sequence of SEQ ID NO:47; and

- [0064] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0065] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - [0066] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
 - [0067] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0068] In some embodiments the antigen-binding molecule comprises:
 - [0069] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0070] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0071] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
 - [0072] HC-CDR3 having the amino acid sequence of SEQ ID NO:49; and
 - [0073] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0074] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - [0075] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
 - [0076] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0077] In some embodiments the antigen-binding molecule comprises:
 - [0078] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0079] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0080] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
 - [0081] HC-CDR3 having the amino acid sequence of SEQ ID NO:50; and
 - [0082] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0083] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - [0084] LC-CDR2 having the amino acid sequence of SEQ ID NO:93
 - [0085] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- [0086] In some embodiments the antigen-binding molecule comprises:
 - [0087] (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - [0088] HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - [0089] HC-CDR2 having the amino acid sequence of SEQ ID NO:45
 - [0090] HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
 - [0091] (ii) a light chain variable (VL) region incorporating the following CDRs:
 - [0092] LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - [0093] LC-CDR2 having the amino acid sequence of SEQ ID NO:92
 - [0094] LC-CDR3 having the amino acid sequence of SEQ ID NO:95.